Drug resistance of bacteremia isolates in a rural hospital in Mozambique (September 3, 2010)

Norwegian role as the “Most Infection Free Country in the World” threatened (September 3, 2010)

Ciprofloxacin no longer drug of choice for Gram-negative infections in Saudia Arabia (September 3, 2010)

Gatifloxacin (TEQUIN) was withdrawn from sale
The FDA issued a notice to determine that TEQUIN (gatifloxacin) Tablets, Injection, and Oral Suspension, were withdrawn from sale for reasons of safety or effectiveness.(October 17, 2008)

Moxifloxacin (AVELOX) and Serious Side Effects
Bayer has sent out letters warning European doctors about a number of reports of serious liver and skin side effects found in patients taking its fluoroquinolone antibiotic, AVELOX(March 17, 2008)

Canadian Levofloxacin Patent Upheld by Federal Appeal Court (June 18, 2007)

US doctors report a case of Torsade de Pointes associated with moxifloxacin use(March 07, 2007)

FDA Panel Urges Limits on Telithromycin (KETEK)
The FDA advisory panel has concluded that telithromycin (KETEK) should not be sold to patients with sinusitis or bronchitis. It could still be used for mild to moderate pneumonia.(December 18, 2006)

Levofloxacin effective in children with recurrent or persistent acute otitis media(December 04, 2006)

FDA has concerns about expanding use of Gemifloxacin (FACTIVE)
Gemifloxacin (FACTIVE), proposed as a treatment for acute sinus infections, should be studied further due to serious skin reactions associated with its use according to FDA documents released on Sep 12, 2006.(September 19, 2006)

A US trial shows that a shorter course of levofloxacin 750 mg for 5 days is just as effective as the longer standard treatment for patients with community-acquired pneumonia(June 05, 2006)